Oral Semaglutide’s Alzheimer’s Hopes Fell Short, but the Drug Hunt Continues

A large phase 3 study of oral semaglutide, a diabetes and weight-loss drug, did not slow Alzheimer’s progression. The result narrows the field, but it also clarifies where the evidence stands.